What are the recommendations for IV Venofer (iron sucrose) administration?

IV Venofer (Iron Sucrose) Administration Recommendations

Venofer should be administered intravenously either as a slow injection over 2-5 minutes or as an infusion over 15 minutes to several hours, depending on the dose and patient population, with dosing tailored to the specific chronic kidney disease (CKD) category. 1

Dosing by Patient Population

Hemodialysis-Dependent CKD (HDD-CKD)

Adults:

• 100 mg undiluted as slow IV injection over 2-5 minutes, OR
• 100 mg diluted in maximum 100 mL of 0.9% NaCl over at least 15 minutes
• Administer during each consecutive hemodialysis session (typically within first hour)
• Usual total treatment course: 1000 mg 1

Pediatric patients (≥2 years):

• 0.5 mg/kg (maximum 100 mg) every 2 weeks for 12 weeks
• Can be given undiluted over 5 minutes OR diluted in 0.9% NaCl (1-2 mg/mL concentration) over 5-60 minutes
• Do not dilute below 1 mg/mL 1

Non-Dialysis Dependent CKD (NDD-CKD)

Adults:

• 200 mg as slow IV injection over 2-5 minutes OR infusion in maximum 100 mL 0.9% NaCl over 15 minutes
• Administer on 5 different occasions over 14-day period
• Alternative: 500 mg diluted in maximum 250 mL 0.9% NaCl over 3.5-4 hours on Day 1 and Day 14 (limited experience) 1

Pediatric patients (≥2 years) on erythropoietin:

• 0.5 mg/kg (maximum 100 mg) every 4 weeks for 12 weeks
• Same administration options as HDD-CKD pediatric dosing 1

Peritoneal Dialysis-Dependent CKD (PDD-CKD)

Adults:

• Three divided doses over 28-day period:
  • Two infusions of 300 mg each over 1.5 hours, 14 days apart
  • One infusion of 400 mg over 2.5 hours, 14 days after second dose
• Dilute in maximum 250 mL 0.9% NaCl 1

Pediatric patients (≥2 years) on erythropoietin:

• Same as NDD-CKD pediatric dosing 1

Safety Monitoring and Administration Protocol

Critical Safety Measures

Monitor patients for hypersensitivity reactions during and for at least 30 minutes after completion of infusion until clinically stable. 1 The 2024 expert consensus guidelines recommend two monitoring options 2:

1. Initiate infusion slowly for approximately 5 minutes, OR
2. Administer 25 mg test dose using syringe with diluted solution slowly over 5 minutes

If no reaction occurs, infuse remaining solution over balance of prescribed time. Stop immediately if hypersensitivity reactions occur 1.

Important Safety Considerations

• True anaphylaxis is very rare with all IV iron formulations 3. Most reactions are complement activation-related pseudo-allergy (infusion reactions), not true anaphylaxis 3
• Serious hypersensitivity reactions, though rare, can be life-threatening—only administer when personnel and therapies for treating serious reactions are immediately available 1
• Monitor for hypotension following each administration, as it may relate to rate of administration and/or total dose 1
• Most reactions occur within 30 minutes of infusion completion 2, 1

Practical Dosing Evidence

Research supports safe administration of 200 mg as 2-minute IV push in CKD patients, with 2,297 injections showing 97.5% proceeding uneventfully (excluding transient metallic taste in 17.9%) 4. However, doses of 400-500 mg have higher adverse event rates and should be avoided or given over longer infusion times 5.

When to Use IV Iron

IV iron is preferred when: 3

• Patient does not tolerate oral iron
• Ferritin levels do not improve with oral iron trial
• Patient has condition where oral iron absorption is unlikely
• Active inflammation present (especially inflammatory bowel disease) 3

Formulations allowing 1-2 infusions to replace iron deficits are preferred over those requiring >2 infusions 3, though Venofer typically requires multiple doses.

Monitoring Parameters

Periodically monitor:

• Hemoglobin and hematocrit
• Serum ferritin and transferrin saturation (TSAT)
• Do not measure serum iron for at least 48 hours after IV dosing as TSAT values increase rapidly 1
• Avoid iron overload—do not administer with evidence of iron overload 1

Common Pitfalls to Avoid

• Never exceed 300 mg per single infusion when using standard infusion times—higher doses (400-500 mg) have unacceptably high adverse event rates 5
• Do not dilute pediatric doses below 1 mg/mL concentration 1
• Avoid rapid administration—slower infusion rates reduce hypotension risk 1
• Do not substitute with iron sucrose "similars" or generics, as complex physicochemical properties make true equivalence difficult 6